102 related articles for article (PubMed ID: 25448583)
1. Formulation, characterization and anti-malarial activity of homolipid-based artemether microparticles.
Agubata CO; Nzekwe IT; Attama AA; Mueller-Goymann CC; Onunkwo GC
Int J Pharm; 2015 Jan; 478(1):202-222. PubMed ID: 25448583
[TBL] [Abstract][Full Text] [Related]
2. Formulation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids.
Chinaeke EE; Chime SA; Onyishi VI; Attama AA; Okore VC
Drug Deliv; 2015; 22(5):652-65. PubMed ID: 24479677
[TBL] [Abstract][Full Text] [Related]
3. Formulation and characterization of hydrochlorothiazide solid lipid microparticles based on lipid matrices of Irvingia fat.
Agubata CO; Chime SA; Kenechukwu FC; Nzekwe IT; Onunkwo GC
Int J Pharm Investig; 2014 Oct; 4(4):189-94. PubMed ID: 25426440
[TBL] [Abstract][Full Text] [Related]
4. Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles.
Agbo C; Umeyor C; Kenechukwu F; Ogbonna J; Chime S; Lovelyn C; Agubata O; Ofokansi K; Attama A
Drug Dev Ind Pharm; 2016 Oct; 42(10):1708-21. PubMed ID: 27095388
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid micro-dispersions (SLMs) based on PEGylated solidified reverse micellar solutions (SRMS): a novel carrier system for gentamicin.
Kenechukwu FC; Momoh MA; Nnamani PO; Attama AA
Drug Deliv; 2015; 22(6):710-22. PubMed ID: 24724962
[TBL] [Abstract][Full Text] [Related]
6. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
7. Development of SMEDDS using natural lipophile: application to beta-Artemether delivery.
Mandawgade SD; Sharma S; Pathak S; Patravale VB
Int J Pharm; 2008 Oct; 362(1-2):179-83. PubMed ID: 18652886
[TBL] [Abstract][Full Text] [Related]
8. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
Attama AA; Müller-Goymann CC
Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
[TBL] [Abstract][Full Text] [Related]
9. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.
Parashar D; Aditya NP; Murthy RS
Drug Deliv; 2016; 23(1):123-9. PubMed ID: 24786480
[TBL] [Abstract][Full Text] [Related]
10. Smart nanocrystals of artemether: fabrication, characterization, and comparative in vitro and in vivo antimalarial evaluation.
Shah SM; Ullah F; Khan S; Shah SM; de Matas M; Hussain Z; Minhas MU; AbdEl-Salam NM; Assi KH; Isreb M
Drug Des Devel Ther; 2016; 10():3837-3850. PubMed ID: 27920499
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.
Patil S; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2013 Oct; 455(1-2):229-34. PubMed ID: 23886650
[TBL] [Abstract][Full Text] [Related]
12. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria.
Joshi M; Pathak S; Sharma S; Patravale V
Int J Pharm; 2008 Oct; 362(1-2):172-8. PubMed ID: 18611435
[TBL] [Abstract][Full Text] [Related]
13. Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa PA; Ugwuoke JA; Attama AA; Ugwu CN; Ezeibe EN; Momoh MA; Echezona AC; Kenechukwu FC
Afr Health Sci; 2020 Dec; 20(4):1679-1697. PubMed ID: 34394228
[TBL] [Abstract][Full Text] [Related]
14. Preparation and Characterization of Solid Dispersions of Artemether by Freeze-Dried Method.
Ansari MT; Hussain A; Nadeem S; Majeed H; Saeed-Ul-Hassan S; Tariq I; Mahmood Q; Khan AK; Murtaza G
Biomed Res Int; 2015; 2015():109563. PubMed ID: 26097842
[TBL] [Abstract][Full Text] [Related]
15. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.
Nnamani PO; Hansen S; Windbergs M; Lehr CM
Int J Pharm; 2014 Dec; 477(1-2):208-17. PubMed ID: 25290810
[TBL] [Abstract][Full Text] [Related]
16. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
17. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
[TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
[TBL] [Abstract][Full Text] [Related]
19. Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
Prabhu P; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2016 Sep; 511(1):473-487. PubMed ID: 27421912
[TBL] [Abstract][Full Text] [Related]
20. Development Insights of Surface Modified Lipid Nanoemulsions of Dihydroartemisinin for Malaria Chemotherapy: Characterization, and in vivo Antimalarial Evaluation.
Umeyor CE; Obachie O; Chukwuka R; Attama A
Recent Pat Biotechnol; 2019; 13(2):149-165. PubMed ID: 30514197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
